Willow Bioscience eyes another use for BioOxi platform with R&D of ursodeoxycholic acid
–News Direct–
Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company.
Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive applications in nutraceutical and pharmaceutical products. UDCA is notably used in the management and treatment of cholestatic liver diseases and gallstone conditions. Moreover, it serves as a crucial intermediate compound for tauroursodeoxycholic acid (TUDCA), an essential active pharmaceutical ingredient in a recently approved combination therapy for the treatment of ALS in Canada and the United States.
In partnership with Sandhill One, LLC, Willow has successfully completed research and development on its UDC...